The Methodist Hospital Research Institute: Prostatic Neoplasms trials
The registry lists 13 Prostatic Neoplasms studies with The Methodist Hospital Research Institute as lead sponsor. 4 are open to participants now and 1 have results posted.
Phase 1 5Phase 2 13(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate CancerNot yet recruitingNCT07796490Phase 1/2
- Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate CancerRecruitingNCT07182279Phase 1/2
- Stem Cells for Erectile Dysfunction Post RALPRecruitingNCT07048314Phase 1/2
- HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate CancerRecruitingNCT01913106Phase 1/2
- 68 Ga-PSMA for High Risk Prostate CancerCompletedNCT04614363Phase 1/2Results posted
- Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & SurgeryStatus unknownNCT03541928Phase 2
- Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate CancerTerminatedNCT00521781Phase 2
- Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate CancerTerminatedNCT00521274Phase 2
- Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate CancerTerminatedNCT00450008Phase 2
- Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate CancerCompletedNCT00448409Phase 2
- Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before ProstatectomyTerminatedNCT00448097Phase 2
- Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate CancerTerminatedNCT00447473Phase 2
- Efficacy and Safety Study of Xyotax to Treat Prostate CancerCompletedNCT00446836Phase 2